ArticleAnnals of hematology2025
Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
The RAS pathway and developmental stage are known to influence leukemic cell proliferation and drug resistance. However, their impact on the prognosis of acute myeloid leukemia (AML) patients, particularly post-allo-HSCT, remains unclear. This study aimed to explore the effects of RAS-pathway mutations and developmental stage on the outcomes of AML patients who received allo-HSCT. A total of 364 consecutive adult AML patients who underwent their first allo-HSCT with myeloablative conditioning were enrolled in this study. The primary endpoint of this study was the cumulative incidence of relapse (CIR) and secondary endpoints were OS and leukemia-free survival (LFS). RAS-pathway mutations were detected in 57 patients (15.7%). Subgroup analysis revealed opposite outcomes: RAS-pathway mutations were associated with a higher cumulative incidence of relapse (CIR) (38.6% vs. 14.8%, P = 0.016) in the primitive AML subgroup and a lower CIR (3.4% vs. 26.8%, P = 0.013) and better leukemia-free survival (LFS) (93.1% vs. 66.9%, P = 0.013) in the monocytic subgroup, compared with AML patients without RAS-pathway mutations. Subgroup multivariable analyses in the primitive subgroup revealed that patients with RAS-pathway mutations had a higher CIR (hazard ratio [HR] = 2.55, 95% confidence interval [CI]: 1.21-5.40). Meanwhile, subgroup multivariable analyses in the monocytic subgroup showed that patients with RAS-pathway mutations exhibited a significantly improved LFS (HR = 0.23, 95% CI: 0.06-0.96). In summary, the prognosis of AML patients with RAS-pathway mutations who received allo-HSCT can be significantly influenced by the developmental stage at which the mutation occurs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.